Abstract P3-12-05: Real-world use of sacituzumab govitecan (SG) in the management of metastatic triple-negative breast cancer (mTNBC) through a Canadian Patient Support Program (PSP)
Bibliographic record
Abstract
Abstract Background: In the ASCENT trial, SG demonstrated significant survival improvements compared to single agent chemotherapy in previously treated mTNBC. Based on these findings, SG was approved by the FDA and Health Canada in 2021 for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received ≥2 prior systemic therapies, at least one of them in the metastatic setting. Here, we report the first study to characterize the real-world use of SG in patients with previously treated mTNBC in Canada. Methods: This was a cohort study of Canadian patients with unresectable locally advanced or metastatic TNBC who received at least one dose of SG between November 2021 and December 2023 via the Gilead Sciences Canada’s Patient Support Program post-approval. Demographic and clinical data were collected as part of PSP enrollment. Patients were followed up until the end of treatment, defined as death, SG discontinuation or lost to follow up, whichever occurred the first. The Kaplan-Meier method was used to estimate treatment duration. Results: A total of 453 patients were identified with a median age of 58 years and mean weight of 71 kg. 245 patients (54%) were primarily treated at a cancer centre and 208 patients (46%) were treated at private infusion Innomar Clinics location. Patients were enrolled in the PSP to receive SG in second-line (2L, 29%); 3L (43%) or 4L+ (28%). The median treatment duration was 4.2 months (95% CI 3.7-4.9). The median dose at treatment initiation was 10.0 mg/kg (IQR, 10.0-10.0) and 355 patients (78%) experienced at least one dose delay and 250 patients (55%) experienced at least one dose reduction. Treatment delay and dose reduction were due to any reason. Among the 323 patients who discontinued treatment, 197 (61%) discontinued due to physician decision in the context of change in patient condition or disease progression. Patients aged < 65 years at enrollment had a median treatment duration of 4.4 months (95% CI 3.7-5.1), whereas those aged ≥ 65 years had a median treatment duration of 3.8 months (95% CI 3.0-5.3). The median treatment duration of SG was 3.7 months (95% CI 3.0-5.3), 4.7 months (95% CI 3.9-5.6), and 3.5 months (95% CI 2.8-4.9) when used in 2L, 3L, and 4L+, respectively with a logrank p=0.2. Conclusions: This study reports real-world SG treatment patterns that are generally consistent with those of the ASCENT trial. These findings support the clinical benefit of SG demonstrated by existing clinical trial data. Potential limitations include the limited capacity of the PSP, the presence of unmeasured confounding, purposive sampling during PSP enrollment, and lack of data linkage. Citation Format: Pierre-Luc Tanguay, Meng Wang, Winson Y. Cheung, A. Anna Cumaraswamy, Philip Q. Ding. Real-world use of sacituzumab govitecan (SG) in the management of metastatic triple-negative breast cancer (mTNBC) through a Canadian Patient Support Program (PSP) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-12-05.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".